Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $31.00 USD
Change Today -0.05 / -0.16%
Volume 226.5K
CTLT On Other Exchanges
Symbol
Exchange
New York
As of 8:04 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

catalent inc (CTLT) Snapshot

Open
$31.09
Previous Close
$31.05
Day High
$31.13
Day Low
$30.94
52 Week High
03/19/15 - $31.66
52 Week Low
07/31/14 - $19.30
Market Cap
3.8B
Average Volume 10 Days
225.1K
EPS TTM
--
Shares Outstanding
124.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CATALENT INC (CTLT)

catalent inc (CTLT) Related Businessweek News

No Related Businessweek News Found

catalent inc (CTLT) Details

Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. It operates through three segments: Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies, including formulation, development, and manufacturing of oral dose forms for prescription and consumer health products. This segment’s oral dose forms include soft gel, modified release technologies, and immediate release solid oral products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development & Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. This segment also offers analytical chemical and cell-based testing and scientific services, stability testing, respiratory products formulation and manufacturing, regulatory consulting, and bioanalytical testing for biologic products. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.

8,300 Employees
Last Reported Date: 09/8/14
Founded in 2007

catalent inc (CTLT) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $850.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $625.0K
Senior Vice President of Global Operations
Total Annual Compensation: $493.1K
Senior Vice President of Global Marketing & S...
Total Annual Compensation: $411.6K
Compensation as of Fiscal Year 2014.

catalent inc (CTLT) Key Developments

Catalent, Inc. Announces Consolidated Unaudited Earnings Results for the Second Quarter and First Half Ended December 31, 2014; Revises Earnings Guidance for the Year Ending June 30, 2015

Catalent, Inc. announced consolidated unaudited earnings results for the second quarter and first half ended December 31, 2014. For the quarter, the company reported net revenue of $455.8 million against $440.7 million a year ago. Operating earnings was $62.4 million against $44.5 million a year ago. Earnings from continuing operations, before income taxes was $42.1 million against $4.4 million a year ago. Earnings from continuing operations were $46.2 million or $0.37 per diluted share against loss from continuing operations of $18.9 million or $0.25 per diluted share a year ago. Net earnings attributable to the company were $46.5 million or $0.37 per diluted share against net loss attributable to the company of $19.2 million or $0.26 per diluted share a year ago. EBITDA from continuing operations was $101.7 million against $83.5 million a year ago. Adjusted EBITDA was $93.4 million against $112.9 million a year ago. Adjusted net income was $55.9 million against $27.9 million a year ago. Revenue growth for both the quarter and year-to-date was driven by strong performance of the Medication Delivery Solutions segment and the modified release technologies business within the Oral Technologies segment, as well as increased demand for analytical services within the Development and Clinical Services segment. For the six months, the company reported net revenue of $874.1 million against $855.0 million a year ago. Operating earnings was $104.9 million against $79.6 million a year ago. Earnings from continuing operations, before income taxes was $7.8 million against loss from continuing operations, before income taxes of $0.4 million a year ago. Earnings from continuing operations were $25.9 million or $0.23 per basic and diluted share against loss from continuing operations of $17.1 million or $0.22 per basic and diluted share a year ago. Net earnings attributable to the company were $27.0 million or $0.23 per diluted share against net loss attributable to the company of $17.7 million or $0.24 per diluted share a year ago. EBITDA from continuing operations was $138.3 million against $156.2 million a year ago. Net cash provided by operating activities was $0.4 million against $40.4 million a year ago. Acquisition of property and equipment and other productive assets was $71.3 million against $39.8 a year ago. For fiscal year ending June 30, 2015, the company now expects revenue to be in the range of $1.82 billion to $1.86 billion, compared to its previous guidance of $1.89 billion to $1.92 billion. The company now expects Adjusted EBITDA to be in the range of $434 million to $444 million, compared to previous guidance of $450 million to $460 million. Adjusted net income is now expected to be in the range of $204 million to $214 million, compared to previous guidance of $215 million to $225 million. In addition, based on the updated operational outlook, capital expenditures are now expected to be in the range of $120 million to $130 million, compared to previous guidance of $115 million to $125 million.

Catalent, Inc. Appoints Thomas Castellano as Vice President Finance, Investor Relations, and Treasurer

Catalent, Inc. announced that it has appointed Thomas Castellano as Vice President Finance, Investor Relations, and Treasurer effective immediately. Mr. Castellano joined Catalent in 2008, when the company formed its Financial Planning and Analysis (FP&A) group and was actively involved in building out its financial operations. His role at Catalent expanded in December 2014, when he was named Treasurer of the Company. Prior to joining Catalent, Mr. Castellano worked with the Capital Markets Finance group at Lehman Brothers, where he held roles of increasing responsibility.

Catalent, Inc. to Report Q2, 2015 Results on Feb 11, 2015

Catalent, Inc. announced that they will report Q2, 2015 results After-Market on Feb 11, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CTLT:US $31.00 USD -0.05

CTLT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Hospira Inc $87.61 USD -0.05
STERIS Corp $70.76 USD +0.06
View Industry Companies
 

Industry Analysis

CTLT

Industry Average

Valuation CTLT Industry Range
Price/Earnings 48.2x
Price/Sales 2.1x
Price/Book 7.8x
Price/Cash Flow 64.9x
TEV/Sales 1.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CATALENT INC, please visit www.catalent.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.